Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial-Reference-Cited by-同舟云学术

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

Published:2007-05 Issue:5 Volume:18 Page:859-867
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mauriac L.,Keshaviah A.,Debled M.,Mouridsen H.,Forbes J.F.,Thürlimann B.,Paridaens R.,Monnier A.,Láng I.,Wardley A.,Nogaret J.-M.,Gelber R.D.,Castiglione-Gertsch M.,Price K.N.,Coates A.S.,Smith I.,Viale G.,Rabaglio M.,Zabaznyi N.,Goldhirsch A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/18/5/859/579789/mdm001.pdf

Reference21 articles.

1. BIG 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer;N Engl J Med,2005

2. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment;Baum;Eur J Cancer,2002

3. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer;Coombes;N Engl J Med,2004

4. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial;Boccardo;J Clin Oncol,2005

5. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial;Jakesz;Lancet,2005

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network;European Journal of Cancer;2024-01

2. Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence;Critical Reviews in Oncology/Hematology;2023-11

3. Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review;Cancers;2022-04-09

4. Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy;Frontiers in Oncology;2021-09-24

5. Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer;npj Breast Cancer;2021-03-01